LEADER 02429nam  2200685Ia 450 
001 9910960106403321
005 20251017110111.0
010   $a9786610179947
010   $a9780309168106
010   $a0309168104
010   $a9781280179945
010   $a1280179945
010   $a9780309526784
010   $a0309526787
035   $a(CKB)111069351132888
035   $a(SSID)ssj0000200600
035   $a(PQKBManifestationID)11184118
035   $a(PQKBTitleCode)TC0000200600
035   $a(PQKBWorkID)10221531
035   $a(PQKB)10535140
035   $a(MiAaPQ)EBC3375838
035   $a(Au-PeEL)EBL3375838
035   $a(CaPaEBR)ebr10046888
035   $a(CaONFJC)MIL17994
035   $a(OCoLC)53989964
035   $a(Perlego)4735243
035   $a(DNLM)1191211
035   $a(EXLCZ)99111069351132888
100   $a20040211d2003      my         0
101 0 $aeng
135   $aurcn|||||||||
181   $ctxt
182   $cc
183   $acr
200 00$aMedicare coverage of routine screening for thyroid dysfunction /$fMarc B. Stone and Robert B. Wallace, editors ; Committee on Medicare Coverage of Routine Thyroid Screening, Board on Health Care Services, Institute of Medicine of the National Academies
205   $a1st ed.
210   $aWashington, D.C. $cNational Academies Pres$dc2003
215   $a135 p
300   $aBibliographic Level Mode of Issuance: Monograph
311 08$a9780309088855 
311 08$a0309088852 
320   $aIncludes bibliographical references.
327   $a1. Introduction -- 2. Pathophysiology and diagnosis of thyroid disease -- 3. Prevelance and consequences of thyroid dysfuntion -- 4. Screening for thyroid dysfuntion -- 5. The cost of coverage -- 6. Conclusions and recommendations.
606   $aThyroid gland$xDiseases
606   $aMedical screening$zUnited States
606   $aMedicare
615  0$aThyroid gland$xDiseases.
615  0$aMedical screening
615  0$aMedicare.
676   $a616.4/4075
701   $aStone$b Marc B$01805823
701   $aWallace$b Robert B.$f1942-$01797965
712 02$aInstitute of Medicine (U.S.).$bCommittee on Medicare Coverage of Routine Thyroid Screening.
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910960106403321
996   $aMedicare coverage of routine screening for thyroid dysfunction$94354642
997   $aUNINA